CAMBRIDGE, Mass., Sept. 21, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Ladenburg Thalmann 2016 Healthcare Conference at Sofitel Hotel in New York City, NY on Tuesday, September 27, 2016, at 11:30am Eastern time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: http://wsw.com/webcast/ladenburg2/vcel.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel‑T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel® and MACI® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 



